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Work package 1 report: description of the current practice of benefit-risk 
assessment for centralised procedure products in the EU regulatory network 
Report by the EMA Benefit-Risk Methodology Project Team 
 
Introduction 
During the March 2008 plenary meeting, the Committee for Human Medicinal Products (CHMP) adopted 
the Reflection Paper on benefit-risk assessment methods in the context of the evaluation of marketing 
authorisation applications of medicinal products for human use (EMEA/CHMP/15404/2007). One of the 
main recommendations for the CHMP was to explore further methodologies for benefit/risk analysis, 
including a wide range of quantitative and semi-quantitative tools, and involving experts and 
assessors. A consequence of this was the initiation of the EMA Benefit-Risk Methodology Project in 
which the five National Competent Authorities (NCAs) of France, The Netherlands, Spain, Sweden and 
UK volunteered to participate. A project team was formed involving experts in the field of decision 
theory. 
The main objective of the EMA Benefit-Risk Methodology Project is the development and testing of 
tools and processes for balancing multiple benefits and risks, which can be used as an aid to informed, 
science-based regulatory decisions about medicinal products. This project is planned to be concluded in 
5 consecutive work packages. The present report constitutes the deliverable of the first work package 
that was intended to describe the current practice of benefit-risk assessment for centralised procedures 
in the EU regulatory network. Included in the report are suggested opportunities for improvements and 
a list of criteria for assessing the usefulness of available tools and processes in the second work 
package. 
Potential tools and processes for regulatory benefit-risk assessment must be adaptable to the current 
practice within the EU regulatory network. This is the reason why the first step of this project was to 
observe how the centralised drug approval process is implemented within each of the five participating 
agencies. 
 
Methods and procedure 
Between June and September 2009, members of the project team were invited to visit five 
participating agencies (Sweden, France, The Netherlands, UK and Spain) for 2-3 days each. The 
purpose of the visits was purely observational, with the aim to extract an overall view of how B/R 
assessments are made Europe-wide. Care was taken to ensure that the visits did not interfere with the 
agencies’ procedures.  
In order to explore each agency’s practice of evaluating and balancing benefits and risks, and to obtain 
a better understanding of the agency’s decision making process, a number of people with a key role in 
the benefit-risk assessment and the regulatory decision making process were interviewed, primarily 
upon suggestion of the agency’s host (CHMP member). The team was also invited to attend a number 
of meetings and observed how the process works in practice. 
The project team interviewed 42 people across the five agencies (5 in Sweden, 6 in France, 9 in the 
Netherlands, 12 in the UK and 10 in Spain), encompassing a variety of roles: agency chairmen and 
directors, heads and co-ordinators of units, CHMP members, statisticians and a number of senior and 
junior assessors with different backgrounds and expertise (e.g., pharmacokinetics, toxicology).  
Interviews were conducted individually for about an hour, with the exception of Spain where group 
interviews were conducted upon suggestion of the Agency’s host. At the beginning of each interview, 
all interviewees were informed that our goal was to understand how they viewed benefits and risks, 
and what broader factors might influence the B-R assessment in their agency, within the scope of the 
centralized drug approval process. They were further assured that all views were anonymous and 
treated confidentially. 
Interviews followed an observation protocol which was devised in May 2009 by the project team, and 
piloted with some internal EMA staff members. Following the first agency visit (Sweden), the protocol 
was subsequently revised and shortened. The observation protocol contained questions under the 
following eight summary headings: 
 
Interview protocol 
 
1) Agency’s history and purpose 
2) Agency’s relationships with governmental and non-
governmental organisations 
3) Agency’s organisational structure 
4) Information flow 
5) Meaning of “benefits” and “risks” 
6) Benefit-risk assessment process 
7) Consistency 
8) Existence of models 
 
(see Annex 1 for the full protocol and sub-questions) 
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 Findings 
Our findings are summarised based on the previous eight summary headings. 
 
1. The Agency’s history and purpose frame the benefit-risk assessment process. 
In all five countries, the NCAs were set up in the 1990s, except for The Netherlands, where the NCA 
dates back to 1963. The thalidomide tragedy provoked legislation that led to the founding of separate 
agencies in several countries, though some form of regulation had existed before, most notably in 
Sweden, whose agency history goes back to 1663 when pharmacy inspections began. All agencies are 
charged with ensuring that approved medicinal products work and are safe, but that requirement can 
be interpreted in different ways, which allows latitude for interpretation on issues of benefits and risks. 
All agencies are now independent bodies, free of political or commercial pressures. Marketing 
authorisation is the final step of the national procedure in all the countries we visited except France, 
where a temporary authorisation for use can be issued. This possibility relieves some of the pressure 
for an early drug approval. The scope of the agencies differs; some are focussed only on human 
medicines, others deal also with medical devices or veterinary medicines. National and/or regional 
decisions about funding are handled in separate organisations (such as the National Institute for Health 
and Clinical Excellence in the UK). 
The Medicines Evaluation Board in The Netherlands is the first regulatory agency to receive an ISO 
9000-2001 certification for its quality management system, which covers the entire approvals process, 
including the people involved. 
 
2. All the Agencies maintain extensive relationships with governmental and non-governmental 
organisations. 
Most of the agencies we visited are increasing their relationships with external health-related bodies.  
Some make their expertise available to other organisations and may even be involved in their decision 
making process as required.  They have established working relationships with universities, hospitals 
and scientists. All agencies often consult external experts for input in their procedures and maintain 
regular contacts with patient and consumer organisations. In the UK a patient representative attends 
the Commission on Human Medicines meetings and in Spain a consumer representative attends the 
Committee for the Evaluation of Medicines (CODEM) meetings. 
To varying degrees, all five agencies consider their role beyond national borders. For example, the 
Swedish Agency’s charter recognises the importance of linking to Europe and the Spanish Agency is 
also involved in Hispano-speaking areas of South America. All recognise a role in a larger European 
network, and they wish to achieve and influence a common view throughout Europe on benefit/risk 
issues. 
 
3. Agency organisational structures vary greatly, some directly affecting benefit/risk assessment, 
others doing so more indirectly. 
It was sometimes difficult to discern the on-the-ground, operating organisation structure of some 
agencies, though all said that the structure affects benefit/risk assessment activities. Sweden and 
France made it clear that they operate a matrix structure, separating the scientific and administrative 
functions; the latter has no accountability for benefit/risk decisions. Separate organisational units in 
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each agency cover some combination of therapeutic areas, safety, quality, pharmacovigilance, herbal 
medicines, novel foods, information processing, generics, OTCs, and veterinary medicinal products. It 
is clear that the structures are more formal in some agencies than in others. In Sweden, for example, 
anyone can talk to anyone else, and the two CHMP members don’t appear at all on the organisation 
chart. Weekly meetings of assessors and this open climate, plus everyone located in one building, 
makes it easy to discuss any issue with whoever has the knowledge. The climate is even easier in 
Spain, where informal contact is the main vehicle for communication. The Dutch, on the other hand, 
are dispersed at three locations, The Hague, Groningen and Nijmegen, so their contact is more formal 
in meetings, which also satisfies the requirements of the ISO process. It is these variations in 
geography and culture that have led to differences in the structures, but all are aimed at ensuring the 
right information and advice is provided to enable benefit/risk judgements to be made.  
 
4. Information flows differ considerably in the agencies, varying from the formal to the informal. 
Dossiers received are usually distributed directly to teams, with the exception of France, where they 
are disseminated to individuals. In France, the clinical assessor receiving the dossier is in charge of the 
efficacy assessment and of assembling the whole assessment report, in close collaboration with 
quality, preclinical, and pharmacovigilance assessors. Informal peer review operates during the 
preparation of the CHMP assessment report. 
In Sweden, the dossier is distributed to five relevant function/task groups: pharmacy/biotech, 
toxicology, pharmacokinetics, clinical and pharmacovigilance. The outputs of each are peer-reviewed 
and then combined into an overall assessment which goes to the Quality Assurance Committee. The 
QAC is advised by an Advisory Group, and the QAC-agreed-assessments are then input to the CHMP. 
A similar process operates in the Netherlands, but with the dossiers going to therapeutic groups, each 
of which assembles a team of internal assessors, plus some external experts. The Product Leader 
ensures that functional area input is provided: quality, pre-clinical, pharmacovigilance, etc.  Informal 
peer review, similar to France, operates during the preparation of the report to the CHMP and at the 
end of the finalisation of the report. Each group is certified ISO, and is responsible for its post-
certification report. 
The groups receiving the dossier in Spain are functional: quality, non-clinical, clinical, 
pharmacovigilance and Quality Review of Documents. Sometimes in Spain the Rapporteur may 
convene a meeting of all relevant parties, but in other cases it is not necessary because a view has 
been formed just through the process of interaction that includes consultations via telephone and 
email. 
The MHRA’s six Product Lifecycle Assessment Teams (PLAT) are organised by therapeutic area: 
cardiovascular and diabetes; respiratory, ear, nose & throat, endocrine and dermatology; central 
nervous system, and anaesthetics; gastrointestinal & nutrition, and blood; anti-infective, obstetrics & 
gynaecology, and urinary tract; musculoskeletal and malignant disease. Each team has its own clinical 
assessors, while the non-clinical assessors, including the quality assessors, go around to different 
PLATs. The reports from PLATs form the basis for the final benefit-risk assessment by the Commission 
for Human Medicines. 
In all the participating agencies, a highly interactive process occurs, with peer review taking place 
informally by senior people guiding junior people, or more formally with separate peer reviews. In 
most agencies the assessors are mainly internal with the exception of Spain where there is a mixture 
of internal and external assessors. External expertise is involved in France, UK and Sweden. 
Interestingly, the Dutch agency uses clinical assessors with diverse scientific backgrounds (not only 
medical doctors). Occasional scepticism was expressed by some assessors about university-based 
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experts who lack clinical experience because they tend to give clear recommendations as if there is no 
uncertainty. In most agencies statisticians advise upon request, with the exception of UK and Sweden 
where statisticians work full time in the agencies and advise all the teams. 
 
5. The meanings of “benefit” and “risk” are very fluid. 
Many interviewees found it difficult to define precisely what is meant by a “benefit”. Most interviewees 
in all agencies agreed that benefits are clinically meaningful improvements to a patient, an 
improvement in health state or quality of life. Others said it was an improvement over a placebo, or at 
least “non-inferior to comparators; a statistically significant effect; a change in the disease 
management of a patient; a better way of delivering a drug; or even a safety improvement. Clearly, 
these definitions go beyond traditional views of efficacy in their concern for effectiveness and, as 
Annex 2 shows, they varied across interviewees within and across agencies. 
An even greater variance within and across agencies was observed when asked to define what is 
meant by a “risk”, which was found more difficult and challenging to answer compared to “benefit”. 
Risk could mean many things: absence of benefit; dangers/hazards for the patient, adverse events, 
direct or indirect harm to the patient, frequency and severity of a side effect; harm to non-patients and 
to the general public; unacceptable damage to the patient; what is lost compared to current therapy; 
the negative aspects of a drug; the inverse of safety; pharmacokinetic interactions; insufficient 
duration; probability of an adverse event or harm; negative impact on quality of life; failure to meet 
endpoints; intolerability; uncertainty surrounding the risks; mortality; “a concept of gambling which 
includes perception”. Many felt that while benefits are objective, risks are not and are more difficult to 
define (See Annex 2 for the list of different definitions of what is a “benefit” and “risk”). Overall, more 
varied definitions were given for risks than for benefits. 
At this point in our interview, we explained to our interviewees that, from a decision-theoretic 
perspective, any drug decision could be decomposed into two broad components: Firstly, the favorable 
(“good things”) or unfavorable (“bad things”) effects for the patient; secondly, the level of uncertainty 
surrounding each of them. 
These two aspects are illustrated in the following 2 by 2 matrix/table, where the first column 
represents the “values” and the second column represents associated “uncertainties”. The strength of 
this representation is that it is backed up by solid decision theory1. 
 
 
 
 
 
 
 
 
 
                                              
1 Goodwin P, Wright G. Decision Analysis for Management Judgment, 4th edition. Chichester: John Wiley; 2009. 
GOOD THINGS 
 
Uncertainty of 
good things 
 
BAD THINGS 
 
Uncertainty of bad 
things 
 
We asked if this four-fold way of thinking could encompass all aspects of benefits and risks, and 
typically the interviewee agreed. Some raised the question about the placement of the adequacy of an 
experimental design in this table, and we explained that it would impact uncertainty about the good or 
bad things, or even both.   
We then asked most of the interviewees to allocate 100 points to each of the four quadrants to reflect 
the time and effort devoted to analysing each cell, on average, for the centralised procedure.  A few 
people felt they couldn’t manage this task, either because different contexts would yield different 
distributions of points, or because their expertise was too specialised to know what was happening in 
all four quadrants. However, 25 people gave specific point distributions (2 managed to give only 
qualitative answers) about the relative time and effort spent on top vs. bottom row or left vs. right 
column. 
The data show great variation in people’s perception of the distribution of time and effort, both within 
and between agencies. Sixteen of the 27 interviewees placed more points on the first column, good 
and bad things, many arguing that these things are clearer in the dossiers than uncertainty. Thirteen 
interviewees said that more time and effort was given to the first row, good things and their 
uncertainty, than the second row, though 9 gave the rows equal importance. Only 5 of the 27 
interviewees gave more points to the bottom row, bad things and their uncertainty. We could not 
discern any consistent pattern that could be associated with the role of the interviewee, except for the 
statisticians, who spend more time and effort on uncertainty, as would be expected. We discovered 
that explanations for the point distributions were not very helpful, especially when we heard the same 
explanation given for opposite distributions. For example, some said that more time was spent on the 
left column because that information was clearer in the dossier than the uncertainties, while others 
said the opposite—because the uncertainties were not so clear presented in the dossier, they spent 
more time on the right column. Overall we were left with the impression that at the beginning of the 
assessment process attention is more concentrated on the left column whereas towards the end of the 
procedure the assessors focus more on the right column, since uncertainty is often highlighted during 
the CHMP discussions. 
The mean number of points in each of the four cells, for the 25 interviewees who gave specific point 
distributions, is shown below. 
 
 
GOOD THINGS 
Mean = 33 
 
Uncertainty of 
good things 
Mean = 25 
 
BAD THINGS 
Mean = 22 
 
Uncertainty of 
bad things 
Mean = 20 
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So, on average, more time and effort is spent on favourable effects and their uncertainty than on 
unfavourable effects and their uncertainty. Most time is spent on favourable effects, least time on the 
uncertainty about unfavourable effects. 
When we asked for the order in which the four cells were addressed in dealing with a dossier, nearly 
everyone started with the upper left cell, arguing if there is no favourable effect, there is no need to 
deal with the rest. But after that start, some interviewees proceeded clockwise around the matrix, 
others went anti-clockwise, and some proceeded left-right on both rows. 
We are left with the impression that this diversity of viewpoint is related to the lack of agreed 
definitions of what represents benefits and risks. It was clear to us that the mental models of the 
interviewees are not structured as in the above 2-by-2 matrix. As Annex 3 shows, there is a great 
convergence in defining benefits as “good things” or favourable effects, as all but three definitions 
given fall in the top left cell of the matrix (with 3 exceptions defining a benefit as something uncertain, 
possible, to be supported by data and statistical tests). On the contrary, there is less convergence in 
the perception and interpretation of risks. The definitions given to “what is a risk” fall across all four 
quadrants, although the majority belongs to the “bad things” (or unfavourable effects) cell, 10 
definitions belong to the “uncertainty of bad things” cell (e.g., frequency of side effect), one belongs to 
the “uncertainty of realizing a good thing” cell and 2 belong to the “good things” quadrant (counting 
risk as the lack of benefit). 
The revised version of the Guidance for the CHMP Day 80 Assessment Report (AR)2 overview uses this 
four-fold model, defining benefits as ‘favourable effects’ and risks as ‘unfavourable effects’. It asks for 
the favourable effects to be described, and also the uncertainty about the knowledge of the favourable 
effects to be explained. Then it asks for the unfavourable effects and their uncertainty to be described. 
This update on the benefit-risk section of the AR was the result of our finding about the lack of 
agreement about the meaning of benefits and risks. 
 
6. The benefit-risk balance is assessed mainly intuitively, the responsibility of an accountable senior 
assessor in some agencies or of a group in other agencies, as a result of extensive discussion. 
Everyone agrees that the benefit-risk balance is a matter of expert judgement, and that this is the 
most difficult step in the approval process. Many pointed to the importance of context: the patient 
population, the severity of the disease, availability of a comparator, etc. The balance is particularly 
difficult to judge “when risks cannot easily be explained to patients”, “when the drug is good on 
efficacy but has serious adverse events”, “when the benefit is smaller than expected”, “when there is 
high uncertainty”, “when the endpoint is not well defined”, “when there are differences of opinion in 
the agency”, “when people may be unduly influenced by recent experience and their feelings may 
spread to the group”, or “when the data aren’t persuasive.” These difficulties are met through further 
discussions, consultations and debate, rarely by a final vote. 
In some agencies, the benefit-risk balance is concluded in a group meeting, and then it is presented by 
the Rapporteur to the CHMP. Feedback from the CHMP is typically reported back to the group. In other 
agencies, the aggregation is done by a senior assessor individually, after the input from the expert 
group discussion is taken into account. 
 
                                              
2 CHMP Day 80 AR Overview Guidance (as adopted in September 2010): 
http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500004800 
7. Consistency is important. 
All agencies highlighted the importance and expressed concern about being consistent in their 
approvals. The EMA Guidelines are/were found useful, and help to create consistency at the European 
level. All agencies rely on the experienced assessors to preserve consistency. In the Netherlands and 
the UK, they look at previous cases to test whether their arguments in the current case are valid, but 
could go in a new direction if the evidence warranted it. In Sweden, their low turnover and the fact 
that everyone is placed in the same building help maintain an intact and accessible regulatory 
memory. In France, they have set up an internal group that discusses monthly cases found to be 
challenging with a view to ensure consistency in the national procedure. Nobody mentioned routinely 
consulting their organisation’s databases for past similar cases. 
 
8. There is no system or model currently used by any agency. 
The only structured support currently used for B/R assessment is the Template-Guidance document for 
the CHMP Day 80 AR. Suggestions from the interviewees for improving the benefit-risk decision 
process included help in translating data to benefits and risks, a good template, spelling out/listing of 
criteria (both short- and long-term), prompts for efficacy, check lists of good and bad things, 
information on whether or not a comparator is important, better structure of the B/R discussion to 
avoid repetition, experienced clinical assessors, training courses, guidelines for the decision process, a 
model from the start (and at every stage) to help cope with the amount of information gathered in the 
assessment, scoring and weighting systems, and input from lay people. Many commented on how well 
the process works now, but all agreed it could be improved. 
 
Discussion and Conclusions 
In the five agencies visited, their history, purpose and current context all impact their organisation 
structure, which in turn affect the process of approving drugs. Some agencies are focused on human 
products, others deal also with animal products and other concerns; some are more self-contained, 
others rely on outside experts; some have adopted more formal procedures, others rely more 
extensively on informal communications; some hold individuals accountable for aspects of the 
regulatory process, others hold groups accountable. There is clearly not one ‘best’ structure or process, 
even though in all five agencies these are tuned to each organisation’s objective of ensuring that 
medicinal products work and are safe.  
A major finding is the variability of interpretations, both within and between agencies, given to ‘benefit’ 
and ‘risk’, particularly to the latter. This divergence of meanings suggests that the mental models 
regulators employ in balancing benefits and risks, in order to arrive at decisions to approve or not, 
may slow down the approval process and could lead to inconsistencies, both of which are concerns of 
regulatory agencies.  On the other hand, group-oriented approval processes, as in the CHMP, can 
provide a means for exploring the differences so that a more robust consensus view can emerge. 
Our suggestion of thinking about benefits and risks in terms of ‘good things’ and ‘bad things’ and the 
uncertainties associated with both, was accepted by all interviewees, and, we consider, could help 
toward clarifying the benefit-risk balance. At the very least, this should improve communication among 
regulators, and at best provide improved transparency and auditability of regulatory decisions.  
In parallel with these findings there was a significant input from the project team to the B/R section of 
the revised template-guidance of the CHMP Day 80 Assessment Report. Based on the experience from 
the interviews with the assessors the team proposed the distinction of benefits and risks to favourable 
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and unfavourable effects, each one linked to its relevant uncertainty. This approach reflects the 2x2 
matrix concept described above and was endorsed in the updated version of the guidance-template. 
Overall, this work package has achieved our goal of gaining an understanding of how European 
regulatory agencies work. In all five agencies, the requirements of the centralised procedure are met, 
but in different ways. While there are many similarities among the countries, we observed substantial 
differences, making it clear to us that our next steps must take account of contextual differences. Any 
form of decision aiding must include a bespoke element, as off-the-shelf decision aids will not be 
universally helpful. 
 
Next steps 
Models could further support the process of making the B/R balance explicit, transparent and 
auditable. They can enhance communication among regulators and between regulators and 
pharmaceutical companies or the public. In exploring the potential usefulness of decision aids, we will 
focus on tools and processes that are fit for purpose, or ‘requisite’, neither overly complex nor too 
simple to be of use. 
In taking account of agency differences, it will be necessary to look carefully at decision aids that can 
be helpful without disrupting the current effective flows of information. In addition, it is evident that 
the helpfulness of a decision aid might be different depending on whether the way of working in an 
agency is more formal or more informal. 
Any decision model/tool has to be evaluated under specific criteria in order to verify its applicability for 
regulatory B/R assessment. Based on previously established knowledge and taking into account 
suggestions for improving the benefit-risk decision reported in paragraph 8, above, we composed a list 
of criteria for appraising tools and processes. This list below includes five major criteria and their sub-
criteria. 
 
1. Logical soundness 
 The overall benefit-risk evaluation is decomposed into separate elements that are 
demonstrated theoretically and/or empirically to be meaningful. 
 The elements are recombined according to a theoretically sound rule. 
 The approach is coherent, that is, it ensures that related decisions based on the approach do 
not contradict each other or the objectives that are to be met. 
 The approach aids rational thinking about benefits and risks. 
 The approach gives results that do not change relative evaluations when alternatives are added 
or removed. 
2. Comprehensiveness 
 The approach can handle any form of data, continuous or discrete, qualitative or quantitative 
data, objective or subjective. 
 The approach can accommodate uncertainty and value judgements, time preferences and risk 
attitudes. 
 The approach makes multiple objectives and trade-offs explicit. 
3. Acceptability of results 
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 The approach provides consistency checks that identify inconsistencies in the data and in 
people’s judgements. 
 The outputs of the approach should be understandable and interpretable in the user’s terms, 
readily understandable and in quantitative form to facilitate comparison between options. 
 The approach should be ‘scrutable’ in that it should make sense to anyone using it and be seen 
as a realistic way to evaluate benefits and risks. 
4. Practicality 
 Implementation of an approach should be economical in the use of participants’ time. 
 The approach should be easy to teach and easy to use. 
 The approach should be adaptable to either formal or informal agency structures. 
 Additions or deletions to the approach should be possible without having to re-do existing 
inputs. 
 Extending a model based on the approach should grow linearly with its inputs. 
 Computer support should be available for any approach, enabling the user to make changes 
quickly and provide immediate feedback.  The functionality of the software should include clear 
and effective graphical displays, and support for sensitivity analyses. 
5. Generativeness 
 The output of the approach should link clearly to action. 
 The approach should provide a clear audit trail so that all aspects of the benefit-risk evaluation 
can be traced. 
 The approach should develop insight and promote learning about benefit-risk evaluation. 
 The approach should transform a fragmented, covert benefit-risk evaluation into an overt 
structure and set of rational processes. 
 The results should be readily communicable and easily understood. 
 
In the second work package we will assess the applicability of existing tools and processes that have 
appeared in the literature and can potentially aid the regulatory B/R assessment. The above list of 
criteria will be the basis for this evaluation. 
 
 
 
 
 
 
 
 
Disclaimer 
This report was sponsored by the European Medicines Agency in the context of the Benefit-risk 
methodology project and the views expressed are those of the authors. 
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Annex 1: Interview protocol used in the cross-agency comparison.  
Observation Protocol 
 
Agency: ___________________________________________________________ 
Date of visit: ________________________________________________________ 
Interviewers: ________________________________________________________ 
___________________________________________________________________ 
Interviewee’s role_____________________________________________________ 
 
The general aim of this questionnaire is to gather information about different practices and to extract 
an overall view of how B/R assessments are made Europe-wide. All views are kept anonymous and will 
be treated confidentially. 
 
Impact on B/R assessment of: 
 
1 Agency’s history and purpose 
 
 We expect that the purpose for which the agency was set up has an impact on how you 
view benefits and risks.  
 
Why was your agency set up and when? 
 
What is it supposed to do? 
 
2 Agency’s relationships with governmental and non-governmental 
organizations 
 
 
 
What relationships do you have with other organizations, both within and outside your 
country and how might they have an impact on B/R assessments? 
 
Do these “external” perspectives enter in the B/R assessments? 
 
Who holds the final authority for approving a drug in your country? 
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3 Agency’s internal structure 
 
 
Does your internal organizational structure reflect or affect how B/R are assessed (pre- 
and post-marketing approval). 
 
Is there an organizational chart available?  If so, use it to explain structure as given on 
the chart. 
 
Does the agency actually work this way? 
 
4 Agency’s information flow 
 
 What is the “flow of information” to and from the EMEA in the process leading to the 
CHMP? 
 
Is this standard, or does this further depend on unit/therapeutic area? 
 
5 How is information for the B/R decision processed? 
  
What does your agency/you think of as “benefit”? 
 
What does your agency/you think of as “risk? 
 
Do you think different people in your agency are agreed on what they mean by benefit 
and risk? 
 
If the answer is: no, what does this variety of views depend on? 
 
Any drug decision can lead to good things and bad things for the patient. Both have 
some uncertainty surrounding them. 
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Imagine you have a pot of 100 points. Please allocate them according to the time and 
effort devoted to analyzing each cell, on average, for the centralized procedure. 
 
Is there a specific order in which you assess info in the “4 quadrants”? 
 
How do people make the B/R balance? 
 
Are there situations in which the B/R balance is difficult to derive?  If so, explain. 
 
How do you come up with an evaluation of the desirability of good and bad things? 
 
How do you deal with uncertainty of good and bad things? 
 
So far we have focused on the benefits and risks of the drugs themselves as patients 
might experience them.  Considering now the perspective of your agency, are any other 
criteria considered in the decision to approve or not?  If so, what are they? 
 
How do you reconcile conflicting views?  
 
Is consensus required and how is it achieved? 
 
Have issues of consistency come up and how do you address them? 
 
What would help the agency to improve the benefit-risk decision? 
 
 
GOOD THINGS 
 
Uncertainty of 
good things 
 
BAD THINGS 
 
Uncertainty of bad 
things 
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6 Is the national agency procedure different?  If yes, how? 
  
7 Is there anything else you would like to contribute? 
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Annex 2: Definitions of Risk and Benefit by NCA 
NCAs Benefits Risks 
1 1. everything good 
2. improvement in health state 
3. effectiveness in the real world 
4. efficacy in clinical trials (equivalent 
to positive effect) 
5. clinical relevance 
6. improvement of illness 
7. potential good effects 
1. all that is negative 
2. inverse of safety 
3. adverse events 
4. loss of efficacy (e.g.) a company’s 
inability to keep quality intact)  
5. kinetic interactions 
6. hurt to patients, variable depending on 
context 
7. side effects 
8. serious adverse effects 
9. reduction in quality 
10. bad effects 
2 1. “drug works”  
2. positive action of a drug 
3. unmet medical need 
4. positive improvement in health 
state that is perceived by patient 
5. everything that improves health or 
reduces problem of safety, efficacy 
in clinical trial  
6. safety improvement 
7. improvement of 
convenience/quality of life for 
patient 
1. danger for the patient  
2. adverse events 
3. likelihood of negative event  
4. inverse of benefit 
5. harm 
6. long term and short term safety profile 
7. frequency and severity of side effect 
8. direct harm on patient 
9. indirect harm through misuse by 
patient 
10. harm on non-patients/general public 
3 1. efficacy for the patient, supported 
by data, externally validated and 
clinically relevant  
2. patient’s function and survival  
3. value compared to the placebo 
4.  non-inferior to comparators 
5. efficacious 
6. an improvement that is meaningful 
to the patient  
7. depends on context 
1. more difficult to define 
2. more difficult to draw hard conclusions 
about 
3. not objective 
4. diverse 
5. linked to benefits 
6. frequent but harmless or infrequent 
but serious 
7. how patients tolerate a drug compared 
to serious side effects like death 
 
Benefit-risk methodology project   
EMA/227124/2011  Page 15/23
 
NCAs Benefits Risks 
8. more than pharmacological activity 
9. pre-defined efficacy for a pre-
defined population 
10. for vaccines, prevention of 
disease; for antibiotics, elimination 
of the microbe; for metabolic 
disease, maintenance; less 
adverse effects 
11. positive effects 
12. a statistically significant effect 
13. changes in the management of a 
patient re disease progression 
8. effects observed after a drug is 
approved 
9. serious events 
10. withdrawal 
11. impact on pregnancies 
12. severity of side effects 
13. chance the benefit won’t be realised 
14. the inverse of short-term and long-
term safety 
15. for vaccines, reactogenicity (e.g., 
fever); development of resistance; 
vaccine failure 
16. possible negative effects (or 
probability) 
17. frequency and severity of side effects 
18. what we don’t want in this compound 
19. depends on the disease 
20. unacceptable damage to the patient 
4 1. an improvement to the patient, 
quality or quantity of life, survival 
2. amelioration of symptoms 
3. suffering reduced,  
4. preventative improvement in 
health and well-being 
5. social benefits,  
6. a measurable change in the right 
direction in a parameter that 
matters 
7. a parameter that everyone agrees 
about 
8. something positive 
9. a good medicine, safe, efficacious 
10. a decent primary endpoint 
translated to the patient being 
better off. 
1. harms 
2. adverse reactions  
3. severity 
4. duration 
5. quality of life 
6. probability of an adverse event or 
harm—trivial or serious 
7. negative impact on quality or quantity 
of life 
8. detriments to health 
9. failure to meet endpoints  
10. not as expected 
11. tolerability 
12. potential or theoretical risks (there is 
still a lot unknown after clinical trials; 
a signal may have been obtained from 
pre-clinical studies) 
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NCAs Benefits Risks 
13. uncertainty surrounding the risks 
14. side effects 
15. mortality  
16. a concept of gambling which includes 
perception 
5 1. easy to perceive 
2. variable between people 
3. dependent on the therapeutic 
area, can improve quality of life 
(hard to measure) 
4. prolong life (easy to measure) 
5. treat disease symptoms 
6. hard to generalise from the 
individual to the population  
7. useful to the patient 
8. anything good for the patient 
9. safety 
10. efficacy and quality 
11. something positive even if 
associated with risks 
12. beneficial to the patient 
13. added value of new therapy over 
the present one 
14. more convenient way of delivering 
the drug 
1. anything harmful to the patient; 
related to quality, safety or lack of 
efficacy 
2. worse in some respect to other 
medicinal products  
3. what you lose compared to current 
therapy 
4. any detrimental effect on the patient 
5. side effects 
6. no benefit  
7. adverse reactions 
8. no treatment 
9. Linked to use of a drug after approval, 
when the risks may be different from 
those observed in the clinical trials, 
especially if the target population were 
to be different 
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Annex 3: 2 x 2 partitioning of benefits and risks (in italic) listed in Annex 2. 
 
Good things Uncertainty of good things 
1. everything good 
2. improvement in health state 
3. effectiveness in the real world 
4. efficacy in clinical trials (equivalent to positive effect) 
5. clinical relevance 
6. improvement of illness 
7.  “drug works”  
8. positive action of a drug 
9. unmet medical need 
10. positive improvement in health state that is perceived 
by patient 
11. everything that improves health or reduces problem 
of safety, efficacy in clinical trial  
12. safety improvement 
13. improvement of convenience/quality of life for patient 
14. patient’s function and survival  
15. value compared to the placebo 
16. non-inferior to comparators 
17. efficacious 
18. an improvement that is meaningful to the patient 
19. depends on context 
20. more than pharmacological activity 
21. pre-defined efficacy for a pre-defined population 
22. for vaccines, prevention of disease; for antibiotics, 
elimination of the microbe; for metabolic disease, 
maintenance; less adverse effects 
23. positive effects 
24. changes in the management of a patient re disease 
progression 
25. an improvement to the patient, quality or quantity of 
life, survival 
26. amelioration of symptoms 
27. suffering reduced,  
28. preventative improvement in health and well-being 
29. social benefits,  
30. a measurable change in the right direction on a 
parameter that matters 
31. a parameter that everyone agrees about 
 
35. efficacy for the patient, supported by 
data, externally validated and clinically 
relevant  
36. potential good effects 
37. a statistically significant effect 
 
 
 
 
 
 
 
 
 
51.    potential or theoretical risks (there 
is still a lot unknown after clinical trials; a 
signal may have been obtained from pre-
clinical studies 
 
Benefit-risk methodology project   
EMA/227124/2011  Page 18/23
 
Good things Uncertainty of good things 
32. something positive 
33. a good medicine, safe, efficacious  
34. a decent primary endpoint translated to the patient 
being better off. 
 
 
 
52. inverse of benefit 
53. linked to benefits 
 
 
 
Bad things Uncertainty of bad things 
1. all that is negative 
2. adverse events 
3. loss of efficacy (e.g. a company’s inability to keep 
quality intact)  
4. kinetic interactions 
5. side effects 
6. serious adverse effects 
7. reduction in quality  
8. bad effects. 
9. danger for the patient  
10. adverse events 
11. harm 
12. long term and short term safety profile 
13. severity of side effect 
14. direct harm on patient 
15. indirect harm through misuse by patient 
16. harm on non-patients/general public 
17. how patients tolerate a drug compared to serious side 
effects like death 
18. effects observed after a drug is approved 
19. serious events 
20. withdrawal 
21. impact on pregnancies 
22. severity of side effects 
23. for vaccines, reactogenicity (e.g., fever); 
development of resistance; vaccine failure 
24. severity of side effects 
41. frequency of side effect 
42. likelihood of negative event  
43. frequent harmless or infrequent but 
serious 
44. chance the benefit won’t be realised 
45. possible negative effects (or 
probability) 
46. probability of an adverse event or 
harm—trivial or serious 
47. not as expected 
48. uncertainty surrounding the risks 
49. a concept of gambling which includes 
perception 
50. hurt to patients, variable depending on 
context 
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Bad things Uncertainty of bad things 
25. what we don’t want in this compound 
26. depends on the disease 
27. unacceptable damage to the patient.  
28. inverse of safety 
29. the inverse of short-term and long-term safety 
30. harms 
31. adverse reactions  
32. severity 
33. duration 
34. quality of life 
35. negative impact on quality or quantity of life 
36. detriments to health 
37. failure to meet endpoints  
38. tolerability 
39. side effects 
40. mortality  
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Annex 4: Visit to Paul-Ehrlich-Institut, 9 February 2010 
 
After completing the visits to the five National Competent Authorities, a visit to the Paul-Ehrlich-
Institut (PEI) in Germany with respect to the specialized areas of vaccines and biomedicines was 
considered of value. 
PEI, in contrast to the other agencies, is divided by product related divisions. In total, 13 assessors 
from the different divisions of PEI were interviewed, following the same method of group interviews as 
in the Spanish agency. These interviews confirmed the key findings previously mentioned in this 
report, namely that there are varying views on what is a risk and a benefit, with risks being generally 
harder to define. Interestingly, perhaps because of the mission and nature of PEI, the interviewees 
mentioned more often than in other agencies a concern for ‘quality’. In line with the fluid distinction 
between risks and benefits, some interviewees described quality as a benefit, others as a risk.  
At PEI, like in the other agencies, there is no structured approach for the benefit-risk balance; the 
weighing and balancing of benefits and risks is an implicit process based on expert judgment that 
varies according to the category of pharmaceutical product (e.g. allergens differ from vaccines). When 
asked to describe the process, assessors at PEI confirmed the implicit process of benefit-risk balance 
that was described in this report: First start from the benefits (“Is there a clinically significant 
benefit?”), next turn to the “risks” side (“look at adverse events”). It was interesting to note that, as in 
the other agencies, the evaluation of risks is acknowledged as being influenced by the initial evaluation 
of benefits. “If so (i.e. if there is a clinically significant benefit), look at adverse events. Are they 
acceptable for the patient?” While this is understandable, this suggests the possibility that a certain 
‘risk factor’ might be assessed as posing higher risks if evaluated after evidence of low benefit than 
after evidence of high benefit. In other words, this suggests that the benefit-risk balance could be 
systematically affected by the order with which information is seen. 
The benefit-risk assessment is generally achieved via group discussion and an established peer review 
system. The fields of advanced therapies and monoclonal antibodies were considered as the most 
challenging in terms of benefit-risk assessment due to multidimensional aspects of benefits and risks. 
Other type of products have harmonised criteria/definitions for assessing benefits and risks, thus 
facilitating the benefit-risk assessment. 
Suggestions made by the assessors for the improvement of the benefit-risk assessment were aligned 
with those expressed in this report, and included: 
- A well structured presentation of the relevant data on benefits and risks 
- A common unit for comparing benefits and risks 
- A thinking tool/model that could add transparency 
- A tool to help them deal with uncertainty and with complicated sets of data 
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Annex 5: Overview of the EMA centralised procedure 
 
Figure: The centralised procedure for approving medicinal products in the European Community. Grey 
arrows indicate information flows. 
 
Table: Timeline for the centralised procedure 
Day Action 
1 Start of the procedure 
80 
Receipt of the Day 80 Assessment Reports with draft list of questions from Rapporteur and 
Co-Rapporteur by CHMP members and EMA. EMA sends reports to the applicant. 
100 
Rapporteur, Co-Rapporteur, other CHMP members and EMA receive comments from 
Members of the CHMP (incl. peer reviewers). 
115 
Receipt of draft list of questions from Rapporteur and Co-Rapporteur, as discussed with the 
peer reviewers, by CHMP members and EMA. 
120 
CHMP adopts the list of questions as well as the overall conclusions and review of the 
scientific data to be sent to the applicant by the EMA. Clock stop 
121 Submission of the responses and restart of the clock. 
150 
Joint Assessment Report from Rapporteur and Co-Rapporteur received by CHMP members 
and EMA. EMA sends joint Assessment Report to the applicant. 
170 
Deadline for comments from CHMP Members to be sent to Rapporteur and Co-Rapporteur, 
EMA and other CHMP Members. 
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Day Action 
180 
CHMP discussion and decision on the need for adoption of a list of outstanding issues and/or 
an oral explanation by the applicant. If an oral explanation is needed, the clock is stopped. 
181 Clock restart and oral explanation (if needed) 
210 Adoption of CHMP Opinion + CHMP Assessment Report 
 
